MilliporeSigma has entered a collaboration with Angiex, Inc. to support the development of Angiex’s lead oncology antibody drug candidate for clinical use. Angiex is developing TM4SF1 as a potential therapy for cancer against a vascular target.  This collaboration is the first project to be undertaken at MilliporeSigma’s new biodevelopment center in Burlington, MA, which will open in October 2017. MilliporeSigma will provide access to process development tools, education programs and tr...